WCM/EADO 2021 | Cemiplimab in advanced BCC

Ketty Peris, MD, Università Cattolica del Sacro Cuore & Universitario A. Gemelli IRCCS, Rome, Italy, describes the interim analysis of a Phase II open label study (NCT03132636) of cemiplimab, a PD-1 inhibitor, in patients with advanced basal cell carcinoma (BCC) that had previously progressed on or were intolerant to hedgehog pathway inhibitors (HHIs). The analysis demonstrated that an objective response rate (ORR) was observed in 31% and 21% of patients with locally advanced BCC and metastatic BCC, respectively, and an acceptable safety profile was recorded. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.